Evidence of impaired bone quality in men with type 1 diabetes: a cross-sectional study.

bone material strength index men microindentation trabecular bone score type 1 diabetes

Journal

Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413

Informations de publication

Date de publication:
13 Aug 2021
Historique:
received: 28 06 2021
accepted: 21 07 2021
pubmed: 22 7 2021
medline: 22 7 2021
entrez: 21 7 2021
Statut: epublish

Résumé

Type 1 diabetes (T1D) is associated with substantial fracture risk. Bone mineral density (BMD) is, however, only modestly reduced, suggesting impaired bone microarchitecture and/or bone material properties. Yet, the skeletal abnormalities have not been uncovered. Men with T1D seem to experience a more pronounced bone loss than their female counterparts. Hence, we aimed to examine different aspects of bone quality in men with T1D. In this cross-sectional study, men with T1D and healthy male controls were enrolled. BMD (femoral neck, total hip, lumbar spine, whole body) and spine trabecular bone score (TBS) were measured by dual x-ray absorptiometry, and bone material strength index (BMSi) was measured by in vivo impact microindentation. HbA1c and bone turnover markers were analyzed. Altogether, 33 men with T1D (43 ± 12 years) and 28 healthy male controls (42 ± 12 years) were included. Subjects with T1D exhibited lower whole-body BMD than controls (P = 0.04). TBS and BMSi were attenuated in men with T1D vs controls (P = 0.016 and P = 0.004, respectively), and T1D subjects also had a lower bone turnover. The bone parameters did not differ between subjects with or without diabetic complications. Duration of disease correlated negatively with femoral neck BMD but not with TBS or BMSi. This study revealed compromised bone material strength and microarchitecture in men with T1D. Moreover, our data confirm previous studies which found a modest decrease in BMD and low bone turnover in subjects with T1D. Accordingly, bone should be recognized as a target of diabetic complications.

Identifiants

pubmed: 34289447
doi: 10.1530/EC-21-0193
pii: EC-21-0193.R1
pmc: PMC8428087
doi:
pii:

Types de publication

Journal Article

Langues

eng

Pagination

955-964

Références

BMC Musculoskelet Disord. 2016 Jul 22;17:308
pubmed: 27448601
J Endocr Soc. 2019 Jul 10;3(10):1799-1818
pubmed: 31528827
Rev Sci Instrum. 2012 Apr;83(4):044301
pubmed: 22559552
J Diabetes Complications. 2006 Sep-Oct;20(5):302-7
pubmed: 16949517
Eur J Endocrinol. 2017 Mar;176(3):R137-R157
pubmed: 28049653
J Bone Miner Res. 2007 Sep;22(9):1317-28
pubmed: 17501667
J Bone Miner Res. 2011 Nov;26(11):2762-9
pubmed: 21887701
J Bone Miner Res. 2017 May;32(5):1062-1071
pubmed: 27943408
Osteoporos Int. 2019 Oct;30(10):2079-2085
pubmed: 31214749
Osteoporos Int. 2010 Feb;21(2):195-214
pubmed: 19760059
Am J Epidemiol. 2007 Sep 1;166(5):495-505
pubmed: 17575306
Bone. 2016 Jan;82:69-78
pubmed: 25722065
J Bone Miner Res. 2016 Jan;31(1):190-5
pubmed: 26234180
J Osteoporos. 2011;2011:651867
pubmed: 21772974
J Clin Endocrinol Metab. 2016 Jun;101(6):2502-10
pubmed: 27115060
Osteoporos Int. 2012 Aug;23(8):2159-67
pubmed: 22080379
Osteoporos Int. 2020 Jan;31(1):175-180
pubmed: 31641800
J Clin Endocrinol Metab. 2017 Apr 1;102(4):1174-1181
pubmed: 28388723
Int J Mol Sci. 2019 Sep 30;20(19):
pubmed: 31575077
Nat Rev Endocrinol. 2017 Apr;13(4):208-219
pubmed: 27658727
Osteoporos Int. 2018 Mar;29(3):733-739
pubmed: 29290026
Calcif Tissue Int. 1992 May;50(5):439-44
pubmed: 1596779
Diabet Med. 2015 Sep;32(9):1134-42
pubmed: 26096918
Front Endocrinol (Lausanne). 2020 Feb 07;11:15
pubmed: 32117052
Basic Clin Pharmacol Toxicol. 2017 Mar;120(3):227-234
pubmed: 27651300
Medicine (Baltimore). 2016 May;95(22):e3042
pubmed: 27258488
Calcif Tissue Int. 2016 Oct;99(4):373-83
pubmed: 27240574
J Clin Densitom. 2018 Apr - Jun;21(2):172-178
pubmed: 28302354
Nutrients. 2013 Jul 31;5(8):3022-33
pubmed: 23912329
Aging Clin Exp Res. 2020 Nov;32(11):2173-2186
pubmed: 31768878
Int J Mol Med. 2011 Sep;28(3):455-62
pubmed: 21567076
Endocr Connect. 2015 Sep;4(3):155-62
pubmed: 26047829
J Bone Miner Res. 2014 Apr;29(4):787-95
pubmed: 24123088
Endocr Rev. 2007 Apr;28(2):151-64
pubmed: 17200084
PLoS One. 2014 Feb 13;9(2):e88946
pubmed: 24551194
Osteoporos Int. 2007 Apr;18(4):427-44
pubmed: 17068657
Sci Rep. 2019 Nov 22;9(1):17353
pubmed: 31757981
Osteoporos Int. 2014 May;25(5):1527-33
pubmed: 24599273
Eur J Epidemiol. 2017 Jul;32(7):593-603
pubmed: 28405867
Diabetes Metab Res Rev. 2014 Oct;30(7):531-42
pubmed: 24376190
J Clin Endocrinol Metab. 1999 Oct;84(10):3666-72
pubmed: 10523012
N Engl J Med. 2006 May 25;354(21):2250-61
pubmed: 16723616
Osteoporos Int. 2016 Jan;27(1):127-33
pubmed: 26187124
Bone. 2021 Jan;142:115685
pubmed: 33049369
J Diabetes Investig. 2015 Nov;6(6):726-33
pubmed: 26543548
Postgrad Med. 1992 Oct;92(5):217-9, 222-4
pubmed: 1409173

Auteurs

Unni Syversen (U)

Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Department of Endocrinology, Trondheim University Hospital (St Olavs Hospital), Trondheim, Norway.

Mats Peder Mosti (MP)

Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Medical Clinic, Trondheim University Hospital (St Olavs Hospital), Trondheim, Norway.

Ida Maria Mynarek (IM)

Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.

Trude Seselie Jahr Vedal (TSJ)

Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.

Kristin Aasarød (K)

Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Department of Gastroenterology, Trondheim University Hospital (St Olavs Hospital), Trondheim, Norway.

Trude Basso (T)

Department of Orthopedics, Trondheim University Hospital (St Olavs Hospital), Trondheim, Norway.

Janne E Reseland (JE)

Department of Biomaterials, University of Oslo, Oslo, Norway.

Per Medbøe Thorsby (PM)

Hormone Laboratory, Department of Medical Biochemistry, Oslo University Hospital, Aker, Oslo, Norway.

Bjorn O Asvold (BO)

Department of Endocrinology, Trondheim University Hospital (St Olavs Hospital), Trondheim, Norway.
K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Trondheim, Norway.

Erik Fink Eriksen (EF)

Department of Biomaterials, University of Oslo, Oslo, Norway.

Astrid Kamilla Stunes (AK)

Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Medical Clinic, Trondheim University Hospital (St Olavs Hospital), Trondheim, Norway.

Classifications MeSH